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Abstract
Only ﬁve species account for 92% of cases of candidemia (Candida albicans, C. glabrata, C. tropicalis, C. parapsilosis, and C. krusei); however,
their distribution varies in population-based studies conducted in different geographical areas. C. albicans is the most frequent species, but
considerable differences are found between the number of cases caused by C. glabrata and C. parapsilosis. Studies from Northern Europe
and the USA reported a high number of cases caused by C. glabrata, whereas studies from Spain and Brazil demonstrated a lower number of
cases caused by C. glabrata and a higher number of cases attributed to C. parapsilosis. Globally, the frequency of C. albicans is decreasing,
while that of C. glabrata and C. krusei is stable, and C. parapsilosis and C. tropicalis are increasing. Patient characteristics and prior antifungal
therapy also have a considerable inﬂuence on the distribution and frequency of Candida spp., regardless of the geographical area. C. albicans
is more frequent in patients aged up to 18 years, the frequency of C. parapsilosis decreases with age, and C. glabrata is more common in the
elderly. Finally, the presence of horizontal transmission of Candida spp. isolates (reported mainly in patients from the adult medical and
post-surgical ICU, patients from oncology–haematology units, and neonates) can affect species distribution.
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Background
Fungal infections have become a major problem in hospitals,
and the number of episodes of sepsis caused by fungi has
been increasing since the early 1990s [1,2]. Candida spp.
remains the most common cause of invasive fungal infections
[3–5], and the incidence of candidemia, which is estimated at
72.8 cases per million inhabitants and year, clearly exceeds
that of invasive aspergillosis and mucormycosis [6]. Candi-
demia is a consequence of advances in health care. During the
last 20 years, we have observed an improvement in diagnostic
procedures, the development and commercialization of new
antifungal agents, and the implementation of strategies to
prevent candidemia; nevertheless, the incidence of candidemia
has increased [7].
Candidemia is generally diagnosed using blood cultures,
although diagnosis remains a challenge for clinicians and micro-
biologists; in fact, half of all cases of invasive Candida infections go
undetected in blood cultures [8]. Given these limitations, the
true epidemiology and incidence of invasive candidiasis is
imprecise. The incidence of candidemia expressed as cases per
100 000 inhabitants has been reported to range from 1 to 8
cases [4]; in a study carried out in Brazil, incidence reported as
cases per 100 000 admissions was higher (249 cases per 100 000
admissions) [9]. In a recent 1-year population-based study
conducted in Spain (29 hospitals, 773 cases), the incidence of
candidemia was 8.1 cases per 100 000 inhabitants, which is
similar to that reported in other European studies [10].
Candidemia has an attributable mortality of 15–35% for
adults and 10–15% for neonates, and the hospitalization cost for
each episode is approximately US$40 000 [11–13]. The rates of
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early and late mortality (7 days and 30 days after diagnosis,
respectively) are different (13% vs. 30%). Whereas early
mortality is associated with factors such as appropriate
antifungal therapy and early removal of central venous cathe-
ters, late mortality is associated with factors related to the
baseline condition of the host [10]. The mortality rate is clearly
correlated with a delay in the initiation of appropriate antifungal
treatment [14,15]. Incorrect treatment includes absence of
antifungal treatment, a delay in initiation, or the use of an
inactive agent. Therefore, efforts to minimize these three
situations should help to reduce the mortality of candidemia.
Knowledge of the frequency of causative species would facilitate
appropriate selection of empirical antifungal treatment.
The distribution of Candida spp. causing candidemia varies in
population-based studies carried out in different geographical
areas. Furthermore, notable differences can also be observed
between hospital units. However, the frequency of Candida
species causing candidemia is also dependent on the predis-
posing conditions of the patients infected, the antifungal agents
they receive, and the local hospital-related factors.
This review discusses global trends in the distribution of
Candida spp. by looking at three main areas: inﬂuence of the
geographic area, inﬂuence of predisposing conditions of the
patients, and inﬂuence of local hospital epidemiology.
Inﬂuence of the Geographical Area
The list of Candida species causing candidemia is long and
continues to expand as a consequence of more precise
identiﬁcation. The ARTEMIS DISK Global Antifungal Surveil-
lance Study includes a large registry of invasive Candida isolates
collected from 127 medical centers worldwide (39 countries).
Data from this registry showed that only ﬁve species
(C. albicans, C. glabrata, C. tropicalis, C. parapsilosis, and C. kru-
sei) accounted for 92% of cases of candidemia [16]. C. albicans
was the most common cause of candidemia worldwide,
accounting for 62% of cases [7,16].
However, the ranking of the abovementioned ‘top 5’
species is variable. Fig. 1 summarizes the proportion of cases
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FIG. 1. Proportion of the most relevant Candida species from population-based studies reporting on candidemia in different countries.
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of candidemia involving the most relevant Candida species from
population-based studies conducted in different countries
[10,17–26]. C. albicans was the main cause of candidemia in
all of them. However, considerable differences were found in
the proportion of cases caused by C. glabrata and C. parapsi-
losis. This ﬁnding has an important clinical impact, as these
species show diminished susceptibility to azoles and echino-
candins, respectively. Studies from Northern Europe and the
USA reported a high number of cases caused by C. glabrata and
a low number of cases caused by C. parapsilosis. In contrast,
reports from Spain and Brazil demonstrated a lower number
of cases caused by C. glabrata and higher number of cases
attributed to C. parapsilosis. The explanation for this ﬁnding is
unknown, although it may be a consequence of the impact of
climate, antifungal policy, or central venous catheter care
procedures.
Compiled data from the ARTEMIS DISK registry are useful
when studying temporal changes in the frequency of invasive
Candida spp isolates in large geographic areas from 1997 to
2007 [16,27,28] (Fig. 2). C. albicans remained the most
frequent species worldwide, although this frequency was
decreasing. The frequency of C. glabrata and C. krusei was
stable, although an increase in the frequency of C. parapsilosis
and C. tropicalis was reported.
Inﬂuence of the Patient’s Predisposing
Conditions
The kind of patient also has a considerable inﬂuence on the
distribution and frequency of Candida spp., regardless of the
geographic area. Malignancies and surgery are common
predisposing factors for the development of candidemia, which
is more frequent at age extremes. In addition, patients
commonly carry central venous catheters and have received
broad-spectrum antibiotics [10,21].
The differences in incidence between adults and children
are also reﬂected in the species distribution. C. albicans is
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FIG. 2. Data compiled from the ARTEMIS DISK registry on the temporal change in species distribution among invasive Candida isolates from 1997
to 2007.
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20 (Suppl. 6), 5–10
CMI Guinea Global trends in Candida species distribution 7
more frequent in patients aged up to 18 years. Interestingly,
the frequency of C. parapsilosis decreases with age, whereas
C. glabrata is more common in the elderly [29,30]. Differ-
ences have also been detected between neonates and adult
patients: C. albicans and C. parapsilosis are more frequent in
neonates (60% vs. 50% and 24% vs. 12%, respectively) [30].
Both species usually cause catheter-related candidemia, and
catheters are widely used in neonates [10]. In contrast, the
frequency of cases caused by azole-resistant species such as
C. glabrata and C. krusei is much lower in neonates (3% vs.
23% and 0% vs. 2%), probably reﬂecting scant use of azoles in
neonatology [30]. A recent study of children in Spain showed
the high percentage of cases of candidemia caused by
C. parapsilosis (47%), which even exceeded that of C. albicans
(37%) [31].
Species distribution is highly dependent on the patient’s
underlying condition. C. glabrata is the most frequently
detected species in stem cell recipients; C. krusei is also
relevant in these patients, probably owing to the widespread
use of azoles in this setting, which may promote infection by
these two azole-resistant species. However, other patients,
such as solid organ recipients, are infected mainly by C. albicans
and C. glabrata [32–34].
A considerable number of episodes of candidemia are
diagnosed in the intensive care unit (ICU) [21,35]. Comparison
of patients admitted to the ICU with those admitted to other
wards reveals no considerable variations in species distribution
[35,36], probably because the species found in the ICU reﬂect
those found in the rest of the hospital [37].
Finally, the use of antifungal agents also has an impact on the
distribution of Candida spp., as shown in a study reporting a
large number of patients collected from all over France [38].
Recent exposure to ﬂuconazole or caspofungin affected the
distribution of Candida spp. by promoting infection by C. glab-
rata and C. krusei (use of ﬂuconazole) and infection by
C. parapsilosis, C. glabrata, and C. krusei (use of caspofungin).
Inﬂuence of Local Hospital Epidemiology
Candida infections can be caused by strains of the patient’s own
microbiota [39,40]. The use of broad-spectrum antibiotics leads
to overgrowth of Candida spp. in the gastrointestinal tract.
Microorganisms can reach the bloodstreamby translocation and
cause candidemia, which is common in patients with mucositis
or after disruption of the skin as a result of colonization.
However, patients can also become infected by exogenous
isolates that are not part of their own microbiota. Exogenous
isolates can colonize the skin, intravenous catheters, and
parenteral infusions and they are often involved in outbreaks
where several patients become infected by the same isolate [41].
Horizontal transmission of exogenous isolates between patients
admitted to the hospital increases the frequency of Candida spp.
and, therefore, the frequency of invasive disease.
Most reported outbreaks of candidemia involved patients
from the adult medical and post-surgical ICU, patients from
oncology–haematology units, and neonates [41]. This ﬁnding
probably reﬂects not only the high number of episodes of
candidemia diagnosed in the units, but also the characteristics
of these patients [7,42–47].
Relatively recent reports on outbreaks of infections caused
by C. parapsilosis show that patients mainly had candidemia and
were admitted to ICUs. Patients were both adult and
paediatric, although neonates were also frequently involved.
Typing of isolates from the patients involved and from the
environment (including health care personnel) showed that
genotypes from patients were commonly found on the hands
of the health care workers, which are a common source of
exogenous isolates [42,45,46,48–51]. Patients’ skin or central
venous catheters can become infected by exogenous isolates
after manipulation of medical devices by health care workers,
particularly in the adult and neonatal ICU. Neonates and adult
patients are also infected by C. albicans. Again, health care
workers play a key role in transmission, and artiﬁcial nails have
been reported to be a possible source of isolates causing an
outbreak [52,53]. In a neonatal ICU, the ﬁrst patient involved
in an outbreak acquired the infection during delivery, and the
isolate was transmitted to the other two patients during
admission to the unit [54].
We recently typed 217 C. albicans isolates from 202 patients
with candidemia admitted to the hospital during a 5-year
period. We found 19 genotypes (11% of the total) that were
epidemic and infected two or more patients. Clusters involved
2–6 patients each, and up to 25% of patients were infected by
epidemic genotypes found in at least one other patient [55].
The same approach was adopted with C. parapsilosis isolates.
We found 78 genotypes, of which 18% were epidemic and
involved 14 clusters [56]. Epidemic genotypes were mostly
detected in neonatology, suggesting more active horizontal
transmission of these pathogens in both units. The higher
frequency of nosocomial transmission may explain the higher
frequency of these two species in neonates than in adult
patients [30].
In conclusion, differences in the distribution of Candida spp
can be found between geographical regions. However, under-
lying condition and antifungal agents received have a consid-
erable effect on local epidemiology. The fact that C. albicans
and C. parapsilosis are transmitted effectively from patient to
patient may contribute to the high number of cases of
candidemia caused by these two species.
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